Abionyx Pharma SA (ABNX) — Cash Flow-to-Debt Ratio
Abionyx Pharma SA (ABNX) has a Cash Flow-to-Debt Ratio of -0.22x as of June 2025, meaning its operating cash flow of €-1.70 Million could theoretically repay 0% of its total liabilities (€7.56 Million) in one year. See Abionyx Pharma SA leverage flexibility ratio to measure the company's free cash flow as a share of total liabilities.
CF-to-Debt Ratio
Operating Cash Flow
Total Liabilities
Data as of
Abionyx Pharma SA Cash Flow-to-Debt Ratio (2013–2024)
Historical debt coverage capacity for Abionyx Pharma SA across 12 annual periods. For the full cash flow conversion analysis, see ABNX cash generation efficiency.
Annual Cash Flow-to-Debt Ratio for Abionyx Pharma SA (2013–2024)
Year-by-year debt coverage analysis for Abionyx Pharma SA. Check cash flow quality index of Abionyx Pharma SA to evaluate the quality of earnings relative to operating cash generation.
| Year | CF-to-Debt Ratio | Operating CF (EUR) | Total Liabilities | YoY Change |
|---|---|---|---|---|
| 2024 | -0.60x | €-3.60 Million | €6.03 Million | ▼ -11.7% |
| 2023 | -0.54x | €-3.70 Million | €6.91 Million | ▼ -37.8% |
| 2022 | -0.39x | €-3.36 Million | €8.65 Million | ▲ +35.3% |
| 2021 | -0.60x | €-6.69 Million | €11.15 Million | ▼ -266.5% |
| 2020 | -0.16x | €-599.00K | €3.66 Million | ▲ +85.2% |
| 2019 | -1.10x | €-3.95 Million | €3.58 Million | ▼ -70.8% |
| 2018 | -0.65x | €-6.00 Million | €9.30 Million | ▲ +33.2% |
| 2017 | -0.97x | €-9.09 Million | €9.41 Million | ▲ +27.2% |
| 2016 | -1.33x | €-19.20 Million | €14.46 Million | ▼ -25.0% |
| 2015 | -1.06x | €-13.71 Million | €12.91 Million | ▼ -248.1% |
| 2014 | -0.31x | €-3.30 Million | €10.82 Million | ▲ +83.7% |
| 2013 | -1.87x | €-14.49 Million | €7.76 Million | — |